MTP Building US Commercial Ops On Edaravone
This article was originally published in PharmAsia News
Executive Summary
Japanese mid-sized firm Mitsubishi Tanabe Pharma is building up its independent US commercial operations with a view to conducting the in-house marketing of new products, starting with an ALS therapy.
You may also be interested in...
Radicava US Approval Boost To Mitsubishi As Sales Decline
The arrival of the first drug for ALS in more than 20 years in the US will also be a boost to its originator Mitsubishi Tanabe's American ambitions.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.